{"id":"lovaza","rwe":[],"tags":[],"trials":[],"_chembl":{"chemblId":"CHEMBL1200711","moleculeType":"Small molecule","molecularWeight":"687.06"},"aliases":["omega-3-acid ethyl esters","Omega-3 fatty acid","Omacor (omega-3-acid ethyl esters) capsules","Omega-3-Acid Ethyl Esters","omega three fatty acids"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$6.5144/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$2,378","description":"LOVAZA 1 GM CAPSULE","retrievedDate":"2026-04-07"}],"offLabel":[],"timeline":[],"_dailymed":{"setId":"21cfa4ce-0b05-47ed-b268-339eb1b83b75","title":"LOVAZA (OMEGA-3-ACID ETHYL ESTERS) CAPSULE [WAYLIS THERAPEUTICS LLC]"},"ecosystem":[],"_scrapedAt":"2026-03-27T23:53:04.743Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT06195306","phase":"PHASE2","title":"Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-07-28","conditions":"Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ","enrollment":66},{"nctId":"NCT06434948","phase":"PHASE2","title":"The Effect of Omega 3 Supplementation on Postoperative Delirium in Elderly Patients Undergoing Major Cardiac Surgery","status":"ENROLLING_BY_INVITATION","sponsor":"University of Missouri-Columbia","startDate":"2026-03-03","conditions":"Postoperative Delirium","enrollment":90},{"nctId":"NCT03598309","phase":"PHASE2","title":"Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-05","conditions":"Lung Diseases, Lung Cancer, Protection Against","enrollment":19},{"nctId":"NCT00682318","phase":"NA","title":"Effects of Fish Oil and Red Wine on Oxidative Stress Biomarkers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Carsten Skarke, MD","startDate":"2008-05","conditions":"Healthy","enrollment":40},{"nctId":"NCT01747447","phase":"NA","title":"VITamin D and OmegA-3 TriaL: Effects on Bone Structure and Architecture (VITAL)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2012-08","conditions":"Bone Density, Body Composition, Bone Health","enrollment":771},{"nctId":"NCT01704859","phase":"NA","title":"VITamin D and OmegA-3 TriaL (VITAL): Fractures, Vitamin D and Genetic Markers","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-06-01","conditions":"Fractures","enrollment":25871},{"nctId":"NCT04573946","phase":"NA","title":"VITamin D and OmegA-3 TriaL: Interrelationship of Vitamin D and Vitamin K on Bone (VITAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2019-07-01","conditions":"Bone Density, Bone Health, Fractures","enrollment":25871},{"nctId":"NCT01653678","phase":"NA","title":"Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2011-11","conditions":"Hypertension","enrollment":25875},{"nctId":"NCT01696435","phase":"NA","title":"VITAL-DEP: Depression Endpoint Prevention in the VITamin D and OmegA-3 TriaL","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2010-07","conditions":"Depression, Depressive Symptoms, Mood","enrollment":18353},{"nctId":"NCT07078422","phase":"NA","title":"Home Use Study of Targeted Mechanical Stimulation for Tremor Relief","status":"RECRUITING","sponsor":"Encora, Inc.","startDate":"2025-01-01","conditions":"Essential Tremor, Parkinson&#39;s Disease","enrollment":80},{"nctId":"NCT01632761","phase":"NA","title":"Effects of Vitamin D and Marine Omega-3 Fatty Acids on Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2012-11","conditions":"Anemia","enrollment":2000},{"nctId":"NCT01169259","phase":"PHASE3","title":"Vitamin D and Omega-3 Trial (VITAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-07","conditions":"Cancer, Cardiovascular Disease","enrollment":25871},{"nctId":"NCT02178410","phase":"PHASE3","title":"VITAL Rhythm Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2012-10","conditions":"Cardiovascular Disease","enrollment":25119},{"nctId":"NCT06343285","phase":"NA","title":"Upper Limb Tremor Reduction in Essential Tremor Patients","status":"COMPLETED","sponsor":"Encora, Inc.","startDate":"2024-01-01","conditions":"Essential Tremor","enrollment":71},{"nctId":"NCT01758081","phase":"NA","title":"Effects of Vitamin D and Omega-3 Fatty Acids on Infectious Diseases and hCAP18 (VITAL Infection)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-07","conditions":"Infections, Human Cathelicidin Antimicrobial Peptide (hCAP-18)","enrollment":25874},{"nctId":"NCT00678743","phase":"PHASE4","title":"An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin","status":"COMPLETED","sponsor":"Provident Clinical Research","startDate":"2007-08","conditions":"Dyslipidemias","enrollment":17},{"nctId":"NCT00135226","phase":"PHASE4","title":"ASCEND: A Study of Cardiovascular Events iN Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2005-03","conditions":"Diabetes Mellitus","enrollment":15480},{"nctId":"NCT00004448","phase":"PHASE2","title":"Alternate Day Prednisone or Daily Fish Oil Supplements in Patients With Immunoglobulin A Nephropathy","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1997-11","conditions":"IgA Glomerulonephritis","enrollment":96},{"nctId":"NCT03018041","phase":"PHASE3","title":"The Long-term Effect of Marine Omega-3 Fatty Acid Supplementation in Renal Transplantation","status":"COMPLETED","sponsor":"Joe Chan","startDate":"2017-09-01","conditions":"Kidney Transplantation","enrollment":174},{"nctId":"NCT03169790","phase":"PHASE1, PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Non Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT03169764","phase":"PHASE1, PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT03175666","phase":"PHASE1, PHASE2","title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Triple Negative Breast Cancer","enrollment":""},{"nctId":"NCT03169777","phase":"PHASE1, PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT03167177","phase":"PHASE1, PHASE2","title":"QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Melanoma","enrollment":""},{"nctId":"NCT03169738","phase":"PHASE1, PHASE2","title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-02","conditions":"Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT03197584","phase":"PHASE1, PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Ovarian Cancer","enrollment":""},{"nctId":"NCT03197571","phase":"PHASE1, PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Urothelial Carcinoma","enrollment":""},{"nctId":"NCT03167164","phase":"PHASE1, PHASE2","title":"QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":"Merkel Cell Carcinoma","enrollment":""},{"nctId":"NCT01728571","phase":"NA","title":"LungVITamin D and OmegA-3 Trial (lungVITAL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2010-07","conditions":"COPD, Asthma, Pulmonary Function","enrollment":25871},{"nctId":"NCT05281562","phase":"PHASE2, PHASE3","title":"Immunonutrition for Diabetic Foot Ulcers","status":"TERMINATED","sponsor":"Prisma Health-Midlands","startDate":"2023-02-08","conditions":"Diabetes Mellitus, Diabetic Peripheral Neuropathy, Diabetic Foot Ulcer","enrollment":1},{"nctId":"NCT03329248","phase":"PHASE1, PHASE2","title":"QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-11-06","conditions":"Pancreatic Cancer","enrollment":6},{"nctId":"NCT00746811","phase":"PHASE4","title":"Effects of Prescription Omega-3 on LDL-C in Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Provident Clinical Research","startDate":"2010-01","conditions":"Primary Hypercholesterolemia","enrollment":32},{"nctId":"NCT02757872","phase":"PHASE3","title":"Effects of Vitamin D and Fish Oil on the Kidney in Hypertensives","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-04","conditions":"Hypertension, Kidney Diseases","enrollment":2232},{"nctId":"NCT01034540","phase":"NA","title":"Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Provident Clinical Research","startDate":"2010-03","conditions":"Hypertriglyceridemia","enrollment":23},{"nctId":"NCT03387098","phase":"PHASE1, PHASE2","title":"QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-12-28","conditions":"Pancreatic Cancer","enrollment":4},{"nctId":"NCT01888211","phase":"NA","title":"Effect of Omega 3 Fatty Acids on Vascular Function","status":"COMPLETED","sponsor":"University of Edinburgh","startDate":"2004-12","conditions":"Previous Myocardial Infarction","enrollment":20},{"nctId":"NCT04268134","phase":"PHASE2","title":"Altering Lipids for Tolerance of Aromatase Inhibitor Therapy","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2020-07-28","conditions":"Breast Cancer","enrollment":77},{"nctId":"NCT01778647","phase":"PHASE4","title":"Omega-3 Fatty Acids as an Adjunctive Therapy for Stimulants in Children With ADHD","status":"TERMINATED","sponsor":"Antonios Likourezos","startDate":"2009-12","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":15},{"nctId":"NCT00743197","phase":"NA","title":"Women With Chest Pain and Normal Coronary Arteries Study","status":"TERMINATED","sponsor":"Northwestern University","startDate":"2008-05","conditions":"Chest Pain","enrollment":3},{"nctId":"NCT05613803","phase":"PHASE3","title":"Poly-unsaturated Fats for Improving Nasal Polyps and Asthma","status":"UNKNOWN","sponsor":"Norfolk and Norwich University Hospitals NHS Foundation Trust","startDate":"2023-10-09","conditions":"Asthma","enrollment":98},{"nctId":"NCT01813110","phase":"NA","title":"Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation","status":"COMPLETED","sponsor":"Penn State University","startDate":"2014-05","conditions":"Inflammatory Responses","enrollment":21},{"nctId":"NCT01782352","phase":"NA","title":"Age-related Macular Degeneration (AMD) in the Vitamin D and Omega-3 Trial (VITAL)","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2010-07","conditions":"Age-related Macular Degeneration","enrollment":25871},{"nctId":"NCT03831698","phase":"PHASE2","title":"Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)","status":"UNKNOWN","sponsor":"University of Kansas Medical Center","startDate":"2019-02-06","conditions":"Colorectal Cancer, Lynch Syndrome","enrollment":21},{"nctId":"NCT01633177","phase":"NA","title":"Study of Vitamin D and Omega-3 Supplementation for Preventing Diabetes","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2010-09","conditions":"Type 2 Diabetes","enrollment":25875},{"nctId":"NCT01669915","phase":"NA","title":"A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2011-09-14","conditions":"Cognitive Decline","enrollment":3424},{"nctId":"NCT03443076","phase":"NA","title":"Bioavailability of EPA + DHA in a SMEDS Formulation","status":"COMPLETED","sponsor":"Midwest Center for Metabolic and Cardiovascular Research","startDate":"2018-02-16","conditions":"Bioavailability","enrollment":24},{"nctId":"NCT00915902","phase":"PHASE2, PHASE3","title":"Fish Oil Study for High Triglyceride Levels in Children","status":"COMPLETED","sponsor":"Babu Balagopal","startDate":"2009-07","conditions":"Hypertriglyceridemia","enrollment":42},{"nctId":"NCT02990091","phase":"PHASE2","title":"Derivatives of Omega-3 HUFA as Biomarkers of Traumatic Brain Injury","status":"WITHDRAWN","sponsor":"University of Pennsylvania","startDate":"2017-01","conditions":"TBI","enrollment":""},{"nctId":"NCT01821833","phase":"NA","title":"Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel","status":"COMPLETED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2016-05-24","conditions":"Breast Cancer, Ovarian Neoplasm, Pain","enrollment":60},{"nctId":"NCT04070833","phase":"NA","title":"Effects of Vitamin D and Omega-3 on Cerebrovascular Disease","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-08-01","conditions":"Stroke, Vitamin D","enrollment":290},{"nctId":"NCT01684722","phase":"NA","title":"Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease","status":"COMPLETED","sponsor":"University of Washington","startDate":"2010-07","conditions":"Diabetes","enrollment":1312},{"nctId":"NCT04308889","phase":"EARLY_PHASE1","title":"Pro-Resolving Mediators in Acute Inflammation in Humans","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-07-02","conditions":"Inflammation; Skin, Resolution, Blister","enrollment":19},{"nctId":"NCT02113163","phase":"PHASE1","title":"PK Study Comparing Metformin Eicosapentaenoate to a Combined Dose of Metformin Hydrochloride and Ethyl Ester EPA","status":"COMPLETED","sponsor":"Thetis Pharmaceuticals LLC","startDate":"2014-03","conditions":"Diabetes Mellitus, Non-Insulin-Dependent, Hypertriglyceridemia","enrollment":32},{"nctId":"NCT01047501","phase":"PHASE3","title":"Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":702},{"nctId":"NCT01047683","phase":"PHASE3","title":"Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2009-12","conditions":"Hypertriglyceridemia","enrollment":229},{"nctId":"NCT01492361","phase":"PHASE3","title":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin","status":"COMPLETED","sponsor":"Amarin Pharma Inc.","startDate":"2011-11","conditions":"Cardiovascular Diseases","enrollment":8179},{"nctId":"NCT01630213","phase":"NA","title":"Impact of Vitamin D Supplementation on Cardiac Structure and Function","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2010-07-01","conditions":"Cardiovascular Disease","enrollment":1025},{"nctId":"NCT01632878","phase":"","title":"Omacor Plus Standard Therapies In Post Myocardial Infarction (MI) Subjects Evaluation: The OPTIMISE Observational Study","status":"COMPLETED","sponsor":"Mylan Inc.","startDate":"2012-07","conditions":"Myocardial Infarction (MI)","enrollment":1531},{"nctId":"NCT04177680","phase":"PHASE2","title":"Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia","status":"COMPLETED","sponsor":"Matinas BioPharma Nanotechnologies, Inc.","startDate":"2020-06-03","conditions":"Hypertriglyceridemia","enrollment":100},{"nctId":"NCT02285166","phase":"","title":"Specified Drug-use Survey of the Granular Capsule Formulation of Omega-3 Fatty Acid Ethyl Esters: OCEAN3","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-10-21","conditions":"Hyperlipidemia","enrollment":15330},{"nctId":"NCT00286234","phase":"PHASE4","title":"Niacin, N-3 Fatty Acids and Insulin Resistance","status":"COMPLETED","sponsor":"University of South Dakota","startDate":"2007-10","conditions":"Metabolic Syndrome, Hypertriglyceridemia","enrollment":68},{"nctId":"NCT00959842","phase":"PHASE1, PHASE2","title":"Effects of Lovaza on Lipoprotein Composition and Function in Mild Hypertriglyceridemia","status":"COMPLETED","sponsor":"Sanford Research","startDate":"2009-09","conditions":"Hypertriglyceridemia","enrollment":15},{"nctId":"NCT04907864","phase":"PHASE2","title":"Effect of Multi-modal Intervention Care on Cachexia in Patients With Advanced Cancer Compared to Conventional Management (MIRACLE)","status":"UNKNOWN","sponsor":"Kil Yeon Lee","startDate":"2020-01-31","conditions":"Gastric Cancer, Colorectal Cancer, Pancreatic Cancer","enrollment":112},{"nctId":"NCT04521465","phase":"","title":"Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye","status":"COMPLETED","sponsor":"Novaliq GmbH","startDate":"2020-11-09","conditions":"Evaporative Dry Eye Disease","enrollment":36},{"nctId":"NCT01785004","phase":"NA","title":"Vitamin D and Omega-3 Adiposity Trial (VITAL Adiposity)","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2012-07","conditions":"Adiposity","enrollment":600},{"nctId":"NCT02996240","phase":"NA","title":"Breast, Omega 3 Free Fatty Acid, Ph 0","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2017-06-12","conditions":"Breastcancer","enrollment":21},{"nctId":"NCT04756180","phase":"PHASE3","title":"An Efficacy and Safety Study of Omega-3-acid Ethyl Ester in Chinese Subjects With Hypertriglyceridemia.","status":"COMPLETED","sponsor":"Abbott","startDate":"2016-10","conditions":"Hypertriglyceridemia","enrollment":248},{"nctId":"NCT01594983","phase":"PHASE2","title":"A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-06","conditions":"Non Familial Chylocmicronemia Syndrome (Non-FCS)","enrollment":58},{"nctId":"NCT03415152","phase":"","title":"A Prospective Observational Program Using Digital Technology Tools to Enhance Patient Adherence to Omacor Therapy","status":"COMPLETED","sponsor":"Abbott","startDate":"2018-01-24","conditions":"History of Myocardial Infarction, Hypertriglyceridemia","enrollment":3000},{"nctId":"NCT01823991","phase":"EARLY_PHASE1","title":"COGNUTRIN in Breast Cancer Survivors","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2014-07-30","conditions":"Breast Cancer","enrollment":36},{"nctId":"NCT04386577","phase":"PHASE3","title":"Effects of Vitamin D and Omega-3 Supplementation on Telomeres in VITAL","status":"UNKNOWN","sponsor":"Augusta University","startDate":"2016-08-19","conditions":"Aging","enrollment":1054},{"nctId":"NCT01041521","phase":"PHASE4","title":"The Impact of Omega Three Fatty Acids on Vascular Function in HIV","status":"COMPLETED","sponsor":"Tufts University","startDate":"2010-01","conditions":"High Triglyceride Level, HIV Infection","enrollment":129},{"nctId":"NCT04242004","phase":"PHASE1, PHASE2","title":"Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2019-10-30","conditions":"Neurocognitive Impairment","enrollment":88},{"nctId":"NCT00760513","phase":"PHASE4","title":"Treatment of Non Alcoholic Fatty Liver Disease With n-3 Fatty Acids","status":"COMPLETED","sponsor":"University Hospital Southampton NHS Foundation Trust","startDate":"2009-11-01","conditions":"Non-Alcoholic Fatty Liver Disease","enrollment":103},{"nctId":"NCT00795717","phase":"PHASE4","title":"Human Immunodeficiency Virus (HIV), Arterial Dysfunction, Lipids, Lovaza (HALO) Trial","status":"COMPLETED","sponsor":"Tufts University","startDate":"2008-07","conditions":"Cardiovascular Disease, HIV Infection","enrollment":41},{"nctId":"NCT01282580","phase":"PHASE1","title":"Dietary Fish and Omega 3 Fatty Acids for Breast Cancer Prevention","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2010-07","conditions":"Breast Cancer","enrollment":25},{"nctId":"NCT01880463","phase":"NA","title":"Dry Eye Disease in the Vitamin D and Omega-3 Trial (VITAL)","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2010-07","conditions":"Dry Eye Disease","enrollment":25875},{"nctId":"NCT02153073","phase":"","title":"Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters","status":"COMPLETED","sponsor":"Takeda","startDate":"2013-05-29","conditions":"Hyperlipidemia","enrollment":3084},{"nctId":"NCT01813006","phase":"PHASE3","title":"Effect of Omega-3 Fatty Acid on Endothelial Function","status":"COMPLETED","sponsor":"Nordlandssykehuset HF","startDate":"2013-03","conditions":"Familial Hypercholesterolemia","enrollment":34},{"nctId":"NCT02824432","phase":"PHASE4","title":"Exploratory Study of the Effect of Omega-3-acid Ethyl Esters (TAK-085) on Vascular Endothelial Function in Patients With Hyperlipidemia by Flow Mediated Dilation","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-08-04","conditions":"Hyperlipidemia","enrollment":37},{"nctId":"NCT00454493","phase":"NA","title":"The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"Olive View-UCLA Education & Research Institute","startDate":"2006-08","conditions":"Coronary Artery Disease","enrollment":71},{"nctId":"NCT02010359","phase":"PHASE4","title":"Fish Oils and Adipose Inflammation Reduction","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2014-06","conditions":"Obesity","enrollment":29},{"nctId":"NCT02839902","phase":"PHASE4","title":"Exploratory Study of the Effects of Omega-3-acid Ethyl Esters on the Lipid and Lipoprotein Profile in the Blood","status":"COMPLETED","sponsor":"Takeda","startDate":"2016-12-27","conditions":"Hyperlipidemia","enrollment":53},{"nctId":"NCT00723398","phase":"NA","title":"Nutritional Supplements and Hormonal Manipulations for Breast Cancer Prevention","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2009-03","conditions":"Breast Cancer","enrollment":266},{"nctId":"NCT00446966","phase":"PHASE4","title":"Fish Oil for Reduction of Atrial Fibrillation After Cardiac Surgery","status":"COMPLETED","sponsor":"Chirag Sandesara","startDate":"2007-02","conditions":"Atrial Fibrillation","enrollment":260},{"nctId":"NCT00577590","phase":"NA","title":"Effects of Fatty Acid Delivery on Heart Metabolism and Function in Type 2 Diabetes (T2DM","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2003-10","conditions":"Diabetes Mellitus, Type II","enrollment":78},{"nctId":"NCT01661764","phase":"PHASE2","title":"Fish Oil Supplementation, Nutrigenomics and Colorectal Cancer Prevention","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2013-02-04","conditions":"Colorectal Adenomatous Polyps","enrollment":141},{"nctId":"NCT00579436","phase":"NA","title":"Effects of Fish Oils on Inflammation and Insulin Resistance","status":"COMPLETED","sponsor":"Philip Kern","startDate":"2007-01","conditions":"Metabolic Syndrome, Insulin Resistance","enrollment":33},{"nctId":"NCT00569686","phase":"NA","title":"Lovaza Therapy of Peripheral Arterial Disease","status":"WITHDRAWN","sponsor":"University of Virginia","startDate":"2007-09","conditions":"Peripheral Artery Disease","enrollment":""},{"nctId":"NCT02899741","phase":"PHASE2","title":"Efficacy of Omega-3 as Adjunctive Therapy for Medically Intractable Epilepsy: A Prospective Open-label Pilot Study","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-08","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT01712867","phase":"NA","title":"The Effect of Phytosterol Esters of Omega-3 (Vayarol) Versus Omega-3 Acids Ethyl Esters in Reducing Triglyceride Levels","status":"COMPLETED","sponsor":"Enzymotec","startDate":"2012-10","conditions":"Patients With Hypertriglyceridemia","enrollment":201},{"nctId":"NCT00504309","phase":"NA","title":"Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides","status":"COMPLETED","sponsor":"Penn State University","startDate":"2007-07","conditions":"Hypertriglyceridemia","enrollment":28},{"nctId":"NCT03438955","phase":"PHASE1","title":"Phase I Drug-drug Interaction of Omega-3 and Atorvastatin","status":"UNKNOWN","sponsor":"DongKoo Bio & Pharma","startDate":"2018-02-01","conditions":"Hyperlipidemia, Hypertriglyceridemia","enrollment":48},{"nctId":"NCT01107964","phase":"NA","title":"Oral Omega-3 Fatty Acids in the Treatment of Dry Eye Syndrome","status":"COMPLETED","sponsor":"Milton S. Hershey Medical Center","startDate":"2010-07","conditions":"Dry Eye Syndrome","enrollment":27},{"nctId":"NCT01155336","phase":"PHASE1, PHASE2","title":"The Effects of Lovaza® in Acute Myocardial Infarction","status":"TERMINATED","sponsor":"University of Rochester","startDate":"2010-06","conditions":"Myocardial Infarction","enrollment":4},{"nctId":"NCT00903409","phase":"PHASE3","title":"Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-11-15","conditions":"Hypertriglyceridemia","enrollment":188},{"nctId":"NCT01624727","phase":"NA","title":"Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2009-06","conditions":"Coronary Heart Disease, Metabolic Syndrome","enrollment":338},{"nctId":"NCT00791089","phase":"PHASE4","title":"Effects of Fish Oil on Post Ablation Arrhythmias","status":"TERMINATED","sponsor":"University of Michigan","startDate":"2008-11","conditions":"Atrial Fibrillation","enrollment":12},{"nctId":"NCT01002118","phase":"NA","title":"Feasibility Study of Omega-3 Fatty Acids in Dialysis Patients","status":"TERMINATED","sponsor":"University of Iowa","startDate":"2008-01-25","conditions":"Cardiovascular Disease","enrollment":1},{"nctId":"NCT00833976","phase":"PHASE4","title":"Omega-3 Fatty Acids (Lovaza) for Second Generation Antipsychotic-Associated Hypertriglyceridemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2009-07","conditions":"High Triglycerides, Hypercholesterolemia, Schizophrenia","enrollment":65}],"_emaApprovals":[],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[{"date":"20110811","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20090420","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20071206","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20080603","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20060703","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20041110","type":"ORIG","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20131115","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20200904","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20150309","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20120831","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20140605","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20080124","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20070612","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20101222","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20090916","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20071107","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20070201","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20130911","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20130626","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20190403","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20140514","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"},{"date":"20110919","type":"SUPPL","sponsor":"WAYLIS THERAP","applicationNumber":"NDA021654"}],"developmentCodes":[],"ownershipHistory":[],"publicationCount":59,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Lovaza","genericName":"Lovaza","companyName":"ImmunityBio, Inc.","companyId":"immunitybio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}